Research programme: bovine-derived polyclonal antibodies - Immuron

Drug Profile

Research programme: bovine-derived polyclonal antibodies - Immuron

Alternative Names: Bovine colostrum powder therapeutics - Immuron; Hyper immune anti UPEC product - Immuron; IMM 160; IMM 252 (HIV microbicide); Shigella vaccine - Immuron/Walter Reed Army Institute of Research

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immuron
  • Developer Immuron; Monash University
  • Class Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Urinary tract infections
  • No development reported HIV infections; Liver cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Liver-cancer in Australia (PO)
  • 16 Jul 2016 No recent reports of development identified for research development in HIV-infections in Australia (PO)
  • 07 Dec 2015 Preclinical trials in Urinary tract infections in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top